MAY 27·SEC EDGARMed
Pham Quang X sold $7K of CVKD
Pham Quang X (CEO and Chairman) sold 1,165 shares of Cadrenal Therapeutics, Inc. (CVKD) at $5.69 on 2026-05-22 under a Rule 10b5-1 trading plan.
StockHealthcare · Biotechnology
$CVKD
Cadrenal Therapeutics, Inc.
Price · $CVKDvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Top stories · $CVKDMore →
MAR 13·TradingView
CVKD: CAD-1005 moves to phase III for HIT, aiming to address a critical unmet need with strong safety data
Cadrenal Therapeutics, Inc.'s CAD-1005, a novel IV therapy for Heparin-Induced Thrombocytopenia (HIT), is progressing to phase III trials following promising phase II results and strong safety data. The drug addresses a significant unmet medical need, has Orphan Drug and Fast Track designations, and may have potential broader applications in diabetes and obesity. This advancement is based on information from a recent virtual investor forum.
FEB 24·Stock Titan
HIT trial: CAD-1005 patients had 50% clot rate vs >75% on placebo
Cadrenal Therapeutics reported encouraging Phase 2 results for CAD-1005 in heparin-induced thrombocytopenia (HIT), showing a greater than 25% absolute reduction in thrombotic events compared to placebo. While the drug did not improve platelet count recovery, patients receiving CAD-1005 experienced fewer thrombotic events (50%) compared to the placebo group (>75%). An End-of-Phase 2 FDA meeting is scheduled for March 2026 to discuss the path forward for a Phase 3 study.